Last reviewed · How we verify
Selegiline Hydrochloride (SELEGILINE)
Selegiline Hydrochloride (SELEGILINE) is a small molecule monoamine oxidase inhibitor (MAOI) developed by Somerset, targeting amine oxidase [flavin-containing] B. It is used to treat major depressive disorder and Parkinson's disease, with FDA approval in 1989. As an off-patent medication, it is not commercially available as a generic. Key safety considerations include its potential for interactions with other medications and foods. Selegiline's half-life is 1.3 hours, with a bioavailability of 4%.
At a glance
| Generic name | SELEGILINE |
|---|---|
| Sponsor | Somerset |
| Drug class | Monoamine Oxidase Inhibitor |
| Target | Amine oxidase [flavin-containing] B |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1989 |
Approved indications
- Major depressive disorder
- Parkinson's disease
Common side effects
- orthostatic hypotension
- nausea/vomiting
- constipation
- weight loss
- anorexia
- poor appetite
- dysphagia
- diarrhea
- heartburn
- rectal bleeding
- bruxism
- gastrointestinal bleeding
Drug interactions
- Alpha/Beta Agonists
- Amphetamines
- Indirectly Acting Sympathomimetic Amines
- Ioflupane I-123
- Selective Serotonin Reuptake Inhibitors
- Serotonin/Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- buspirone
- cyclobenzaprine
- dextromethorphan
- entacapone
- levodopa
Key clinical trials
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects (PHASE1)
- Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects
- Selegiline to Zelapar Switch Study in Parkinson Disease Patients (PHASE4)
- Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers (PHASE1)
- Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients (PHASE2)
- Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease (PHASE4)
- Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease (PHASE4)
- Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selegiline Hydrochloride CI brief — competitive landscape report
- Selegiline Hydrochloride updates RSS · CI watch RSS
- Somerset portfolio CI